Regulatory Approvals - In September 2025, argenx received approval in Japan for VYVDURA prefilled syringe for self-injection for treating adult patients with generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy [152]. - In July 2025, Janssen announced European Commission approval for a new indication for DARZALEX SC as a monotherapy for high-risk adult patients with smoldering multiple myeloma [152]. - In June 2023, argenx received FDA approval for VYVGART Hytrulo for generalized myasthenia gravis, followed by European Commission approval in November 2023 and Japan approval in January 2024 [178]. - In July 2023, argenx reported positive data from the ADHERE study for VYVGART Hytrulo in chronic inflammatory demyelinating polyneuropathy, with FDA approval announced in June 2024 [178]. - OCREVUS SC received EU marketing authorization in June 2024 for a ten-minute injection, administered twice a year for multiple sclerosis [164]. - Takeda's HYQVIA received FDA approval for treating Primary Immunodeficiency in children in April 2023, expanding its use [169]. - BMS's Opdivo Qvantig, the first SC programmed death 1 inhibitor, received FDA approval in December 2024 for multiple adult solid tumors [176]. - Roche's TECENTRIQ SC was approved by the FDA in September 2024, further enhancing its market presence [163]. Collaborations and Acquisitions - Halozyme agreed to acquire Elektrofi, Inc. for $750 million upfront and up to three $50 million milestone payments contingent on product regulatory approvals, expected to close in Q4 2025 [152]. - The company licenses its ENHANZE technology to major biopharmaceutical companies, enhancing the delivery of high-dose injectable biologics [148]. - Halozyme's collaborations include partnerships with Roche, Takeda, Pfizer, Janssen, AbbVie, Lilly, BMS, argenx, ViiV, Chugai, and Acumen [149]. - In November 2023, argenx entered into a collaboration with Acumen to explore the use of ENHANZE for ACU193, targeting early Alzheimer's disease [185]. - In March 2025, ViiV announced that N6LS administered every four months with ENHANZE successfully maintained viral suppression in adults living with HIV [182]. Product Development and Technology - Halozyme has commercialized auto-injector products with Teva and Otter, and has development programs with McDermott Laboratories Limited [150]. - Halozyme's proprietary product portfolio includes Hylenex and XYOSTED, utilizing rHuPH20 and auto-injector technology respectively [150]. - ENHANZE technology may reduce patient treatment burden by enabling shorter administration times compared to intravenous methods [148]. - ATRS-1902 is a proprietary drug-device combination product for adrenal crisis rescue, with a Phase 1 clinical study initiated in September 2021 [158]. - Positive results from the Phase 1 study of ATRS-1902 led to Fast Track designation by the FDA, advancing the program to a pivotal study [159]. - The FDA accepted the IND application for ATRS-1902, allowing the initiation of clinical studies to compare its pharmacokinetics with Solu-Cortef [158]. - The company is actively expanding its product portfolio through collaborations and new product candidates in the pipeline [154]. Financial Performance - Royalties for the three months ended September 30, 2025, were $236,038, a 52% increase from $155,061 in 2024, driven by sales of ENHANZE partner products [192]. - Proprietary product sales for the three months ended September 30, 2025, were $52,242, a 31% increase from $39,925 in 2024, primarily due to market penetration of XYOSTED [192]. - Total product sales, net for the three months ended September 30, 2025, were $94,228, a 9% increase from $86,659 in 2024 [192]. - Revenues under collaborative agreements for the three months ended September 30, 2025, were $23,998, a 50% decrease from $48,364 in 2024, primarily due to timing of milestones achieved [194]. - Royalties for the nine months ended September 30, 2025, increased by 52% to $609,869,000 compared to $400,572,000 in 2024, driven by sales of ENHANZE partner products [202]. - Total product sales, net for the nine months ended September 30, 2025, increased by 13% to $253,779,000 from $224,128,000, primarily due to increased sales of proprietary product XYOSTED [203]. - Revenues under collaborative agreements decreased by 12% to $81,196,000 from $92,616,000, primarily due to the timing of milestones achieved [204]. Operating Expenses and Cash Flow - Operating expenses for the three months ended September 30, 2025, increased by 12% in cost of sales to $55,242,000 compared to $49,426,000 in 2024 [195]. - Research and development expenses decreased by 7% to $17,251,000 from $18,458,000, primarily due to lower compensation expenses [197]. - Selling, general and administrative expenses rose by 12% to $46,088,000, driven by increased consulting and professional service fees, including $6,000,000 in litigation costs [198]. - Investment and other income, net decreased by 18% to $5,333,000 from $6,474,000, mainly due to lower market interest rates [199]. - Income tax expense increased by 55% to $43,733,000 from $28,136,000, attributed to higher income before tax [201]. - Net cash provided by operating activities increased by $131,932,000 to $432,529,000 for the nine months ended September 30, 2025 [212]. - As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $702,000,000, sufficient to fund operations for at least the next 12 months [210]. Debt and Financing - As of September 30, 2025, the conditional conversion feature of the 2028 Convertible Notes was triggered, classifying them as current portion of long-term debt [219]. - The initial conversion rate for the 2028 Convertible Notes is 17.8517 shares per $1,000 principal amount, equivalent to a conversion price of approximately $56.02 per share [220]. - The cap price of the Capped Call Transactions is initially $75.4075 per share, representing a 75% premium above the last reported sale price of $43.09 per share on August 15, 2022 [221]. - The company paid approximately $69.1 million for the Capped Calls, recorded as a reduction to additional paid-in capital [222]. - The company completed the sale of $805.0 million in aggregate principal amount of 0.25% Convertible Senior Notes due 2027, with net proceeds of approximately $784.9 million after fees [223]. - The initial conversion rate for the 2027 Convertible Notes is 12.9576 shares per $1,000 principal amount, equivalent to a conversion price of approximately $77.17 per share [226]. - The 2022 Credit Agreement provides for a $575 million revolving credit facility and a $250 million term loan facility, maturing on November 30, 2026 [227]. - The Term Facility requires quarterly repayments of 2.50%, 5.00%, 7.50%, and 10.00% of the initial principal amount in the first four years, respectively [228]. - As of September 30, 2025, the revolving credit facility was undrawn [230]. - The company does not believe that an immediate change of 10% in interest rates would materially impact its results of operations [237].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ……………..to …………….. Commission File Number: 814-00061 CAPITAL SOUTHWEST CORPORATION (Exact name of registrant as specified in its charter) Texas 75-1072796 ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the transition period from to Commission File Number 001-42509 STRATEGY INC (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpora ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware (State or other jurisdiction of incorporation or organization) 51-0323571 (I.R.S. Employer Identification Number) For the transition period from to Commission File Number 001-4 ...

Page 1 of 23 IAC REPORTS Q3 2025 Repurchased 2.8 million shares since Q2 2025 earnings for an aggregate of $100 million People Inc. Q3 Digital revenue growth of 9%; signs AI licensing deal with Microsoft People Inc. FY 2025 Operating Income guidance of $180-$200 million and Adjusted EBITDA guidance of $325-$340 million NEW YORK— November 3, 2025—IAC (NASDAQ: IAC) released its third quarter results today and separately posted a Q3 2025 earnings presentation on the Investor Relations section of its website at ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-42509 STRATEGY INC (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpora ...

Clorox Reports Q1 Fiscal Year 2026 Results, Updates Outlook Reports sales and earnings decline primarily due to expected impact of ERP transition OAKLAND, Calif., November 3, 2025 — The Clorox Company (NYSE: CLX) today reported results for the first quarter of fiscal year 2026, which ended September 30, 2025. First-Quarter Fiscal Year 2026 Summary Following is a summary of key results for the first quarter, which reflects the impact from incremental shipments associated with the enterprise resource planning ...

Exhibit 99.2 ThredUp Inc. Third Quarter 2025 Supplemental Financials All results reported are for continuing operations, unless otherwise noted. Key Financial Metrics for the Quarter Financial Outlook For fourth quarter 2025, ThredUp expects: For fiscal year 2025, ThredUp expects: Conference Call and Webcast • The live and archived webcast and all related earnings materials will be available at ThredUp's investor relations website: ir.thredup.com/news- events/events-and-presentations. 1 • Revenue of $82.2 m ...

As filed with the Securities and Exchange Commission on November 3, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____. Commission File Number 001-14951 FEDERAL AGRICULTURAL MORTGAGE CORPORATION ( ...

As filed with the Securities and Exchange Commission on November 3, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or FEDERAL AGRICULTURAL MORTGAGE CORPORATION (Exact name of registrant as specified in its charter) Federally chartered instrumentality of the United States 52-1578738 (State or other jurisdiction of incorporation or ...